Patents by Inventor Joseph E. Rabinowitz
Joseph E. Rabinowitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132912Abstract: A CpG-modified recombinant adeno-associated viral (AAV) vector is described. The vector carries a nucleic acid molecule comprising AAV inverted terminal repeat (ITR) sequences and an exogenous gene sequence under the control of regulatory sequences which control expression of the gene product, in which the nucleic acid sequences carried by the vector are modified to significantly reduce CpG di-nucleotides such that an immune response to the vector is reduced as compared to the unmodified AAV vector. Also provided are methods and regimens for delivering transgenes using these AAV viral vectors, in which the innate immune response to the vector and/or transgene is significantly modulated.Type: ApplicationFiled: August 6, 2023Publication date: April 25, 2024Inventor: Joseph E. Rabinowitz
-
Publication number: 20220154208Abstract: A CpG-modified recombinant adeno-associated viral (AAV) vector is described. The vector carries a nucleic acid molecule comprising AAV inverted terminal repeat (ITR) sequences and an exogenous gene sequence under the control of regulatory sequences which control expression of the gene product, in which the nucleic acid sequences carried by the vector are modified to significantly reduce CpG di-nucleotides such that an immune response to the vector is reduced as compared to the unmodified AAV vector. Also provided are methods and regimens for delivering transgenes using these AAV viral vectors, in which the innate immune response to the vector and/or transgene is significantly modulated.Type: ApplicationFiled: May 11, 2021Publication date: May 19, 2022Inventors: Susan M. Faust, Joseph E. Rabinowitz, James M. Wilson
-
Patent number: 11015210Abstract: A CpG-modified recombinant adeno-associated viral (AAV) vector is described. The vector carries a nucleic acid molecule comprising AAV inverted terminal repeat (ITR) sequences and an exogenous gene sequence under the control of regulatory sequences which control expression of the gene product, in which the nucleic acid sequences carried by the vector are modified to significantly reduce CpG di-nucleotides such that an immune response to the vector is reduced as compared to the unmodified AAV vector. Also provided are methods and regimens for delivering transgenes using these AAV viral vectors, in which the innate immune response to the vector and/or transgene is significantly modulated.Type: GrantFiled: April 15, 2016Date of Patent: May 25, 2021Inventors: Susan M. Faust, Joseph E. Rabinowitz, James M. Wilson
-
Publication number: 20160222414Abstract: A CpG-modified recombinant adeno-associated viral (AAV) vector is described. The vector carries a nucleic acid molecule comprising AAV inverted terminal repeat (ITR) sequences and an exogenous gene sequence under the control of regulatory sequences which control expression of the gene product, in which the nucleic acid sequences carried by the vector are modified to significantly reduce CpG di-nucleotides such that an immune response to the vector is reduced as compared to the unmodified AAV vector. Also provided are methods and regimens for delivering transgenes using these AAV viral vectors, in which the innate immune response to the vector and/or transgene is significantly modulated.Type: ApplicationFiled: April 15, 2016Publication date: August 4, 2016Inventors: Joseph E. Rabinowitz, James M. Wilson, Susan M. Faust
-
Patent number: 9012224Abstract: The present invention is based, in part, on the discovery that parvovirus (including AAV) capsids can be engineered to incorporate small, selective regions from other parvoviruses that confer desirable properties. The inventors have discovered that in some cases as little as a single amino acid insertion or substitution from a first parvovirus (e.g., an AAV) into the capsid structure of another parvovirus (e.g., an AAV) to create a chimeric parvovirus is sufficient to confer one or more of the desirable properties of the first parvovirus to the resulting chimeric parvovirus and/or to confer a property that is not exhibited by the first parvovirus or is present to a lesser extent.Type: GrantFiled: January 3, 2011Date of Patent: April 21, 2015Assignees: The University of North Carolina at Chapel Hill, The University of Florida Research FoundationInventors: Dawn E. Bowles, Chengwen Li, Joseph E. Rabinowitz, Josh Grieger, Mavis Agbandje-McKenna, Richard Jude Samulski
-
Publication number: 20140271550Abstract: A CpG-modified recombinant adeno-associated viral (AAV) vector is described. The vector carries a nucleic acid molecule comprising AAV inverted terminal repeat (ITR) sequences and an exogenous gene sequence under the control of regulatory sequences which control expression of the gene product, in which the nucleic acid sequences carried by the vector are modified to significantly reduce CpG di-nucleotides such that an immune response to the vector is reduced as compared to the unmodified AAV vector. Also provided are methods and regimens for delivering transgenes using these AAV viral vectors, in which the innate immune response to the vector and/or transgene is significantly modulated.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicants: The Trustees of the University of Pennsylvania, Thomas Jefferson UniversityInventors: Joseph E. Rabinowitz, James M. Wilson, Susan M. Faust
-
Patent number: 8383601Abstract: The invention provides nucleic acid segments, compositions and methods for the treatment of heart failure, vascular dysfunction, endothelial dysfunction, diabetes, [Ca2+]i regulation and NO synthase dysfunction. Adeno-associated and adenovirus are used as gene delivery vectors for the nucleic acid segments to product long term over-expression of S100A1, a small calcium sensing protein associated with the disclosed ailments and dysfunctions.Type: GrantFiled: October 30, 2007Date of Patent: February 26, 2013Assignee: Thomas Jefferson UniversityInventors: Walter J. Koch, Patrick Most, Sven T. Pleger, Joseph E. Rabinowitz
-
Publication number: 20110104119Abstract: The present invention is based, in part, on the discovery that parvovirus (including AAV) capsids can be engineered to incorporate small, selective regions from other parvoviruses that confer desirable properties. The inventors have discovered that in some cases as little as a single amino acid insertion or substitution from a first parvovirus (e.g., an AAV) into the capsid structure of another parvovirus (e.g., an AAV) to create a chimeric parvovirus is sufficient to confer one or more of the desirable properties of the first parvovirus to the resulting chimeric parvovirus and/or to confer a property that is not exhibited by the first parvovirus or is present to a lesser extent.Type: ApplicationFiled: January 3, 2011Publication date: May 5, 2011Inventors: Dawn E. Bowles, Chengwen Li, Joseph E. Rabinowitz, Josh Grieger, Mavis Agbandje-McKenna, Richard Jude Samulski
-
Patent number: 7923436Abstract: The invention uses recombinant parvoviruses, and particularly recombinant adeno-associated virus (rAAV) to deliver genes and DNA sequences for gene therapy following manipulation of the therapeutic virus for packaging and transport. The invention delivers therapeutic viral vectors via rAAV affixed to support matrixes (i.e., sutures, surgically implantable materials, grafts, and the like).Type: GrantFiled: April 5, 2007Date of Patent: April 12, 2011Assignee: University of North Carolina - Chapel HillInventors: Paul E. Monahan, Richard Jude Samulski, Joseph E. Rabinowitz
-
Patent number: 7892809Abstract: The present invention is based, in part, on the discovery that parvovirus (including AAV) capsids can be engineered to incorporate small, selective regions from other parvoviruses that confer desirable properties. The inventors have discovered that in some cases as little as a single amino acid insertion or substitution from a first parvovirus (e.g., an AAV) into the capsid structure of another parvovirus (e.g., an AAV) to create a chimeric parvovirus is sufficient to confer one or more of the desirable properties of the first parvovirus to the resulting chimeric parvovirus and/or to confer a property that is not exhibited by the first parvovirus or is present to a lesser extent.Type: GrantFiled: December 15, 2005Date of Patent: February 22, 2011Assignees: The University of North Carolina at Chapel Hill, The University of Florida Research FoundationInventors: Dawn E. Bowles, Chengwen Li, Joseph E. Rabinowitz, Josh Grieger, Mavis Agbandje-McKenna, Richard Jude Samulski
-
Publication number: 20100190840Abstract: The invention provides nucleic acid segments, compositions and methods for the treatment of heart failure, vascular dysfunction, endothelial dysfunction, diabetes, [Ca2+]i regulation and NO synthase dysfunction. Adeno-associated and adenovirus are used as gene delivery vectors for the nucleic acid segments to product long term over-expression of S100A1, a small calcium sensing protein associated with the disclosed ailments and dysfunctions.Type: ApplicationFiled: October 30, 2007Publication date: July 29, 2010Applicant: THOMAS JEFFERSON UNIVERSITYInventors: Walter J. Koch, Patrick Most, Sven T. Pleger, Joseph E. Rabinowitz
-
Publication number: 20080269149Abstract: The present invention is based, in part, on the discovery that parvovirus (including AAV) capsids can be engineered to incorporate small, selective regions from other parvoviruses that confer desirable properties. The inventors have discovered that in some cases as little as a single amino acid insertion or substitution from a first parvovirus (e.g., an AAV) into the capsid structure of another parvovirus (e.g., an AAV) to create a chimeric parvovirus is sufficient to confer one or more of the desirable properties of the first parvovirus to the resulting chimeric parvovirus and/or to confer a property that is not exhibited by the first parvovirus or is present to a lesser extent.Type: ApplicationFiled: December 15, 2005Publication date: October 30, 2008Inventors: Dawn E. Bowles, Chengwen Li, Joseph E. Rabinowitz, Josh Grieger, Mavis Agbandje-McKenna, Richard Jude Samulski
-
Patent number: 7201898Abstract: The invention uses recombinant parvoviruses, and particularly recombinant adeno-associated virus (rAAV) to deliver genes and DNA sequences for gene therapy following manipulation of the therapeutic virus for packaging and transport. The invention delivers therapeutic viral vectors via rAAV affixed to support matrixes (i.e., sutures, surgically implantable materials, grafts, and the like).Type: GrantFiled: June 1, 2001Date of Patent: April 10, 2007Assignee: The University of North Carolina at Chapel HillInventors: Paul E. Monahan, Richard Jude Samulski, Joseph E. Rabinowitz
-
Patent number: 7172893Abstract: The present invention provides genetically-engineered parvovirus capsids and viruses designed to introduce a heterologous gene into a target cell. The parvoviruses of the invention provide a repertoire of vectors with altered antigenic properties, packaging capabilities, and/or cellular tropisms as compared with current AAV vectors.Type: GrantFiled: July 26, 2002Date of Patent: February 6, 2007Assignee: University of North Carolina at Chapel HillInventors: Joseph E. Rabinowitz, Richard Jude Samulski, Weidong Xiao
-
Publication number: 20040013645Abstract: The invention uses recombinant parvoviruses, and particularly recombinant adeno-associated virus (rAAV) to deliver genes and DNA sequences for gene therapy following manipulation of the therapeutic virus for packaging and transport. The invention delivers therapeutic viral vectors via rAAV affixed to support matrixes (i.e., sutures, surgically implantable materials, grafts, and the like).Type: ApplicationFiled: December 19, 2002Publication date: January 22, 2004Inventors: Paul E. Monahan, Richard Jude Samulski, Joseph E. Rabinowitz
-
Publication number: 20030053990Abstract: The present invention provides genetically-engineered parvovirus capsids and viruses designed to introduce a heterologous gene into a target cell. The parvoviruses of the invention provide a repertoire of vectors with altered antigenic properties, packaging capabilities, and/or cellular tropisms as compared with current AAV vectors.Type: ApplicationFiled: July 26, 2002Publication date: March 20, 2003Applicant: University of North Carolina at Chapel HillInventors: Joseph E. Rabinowitz, Richard Jude Samulski, Weidong Xiao
-
Patent number: 6491907Abstract: The present invention provides genetically-engineered parvovirus capsids and viruses designed to introduce a heterologous gene into a target cell. The parvoviruses of the invention provide a repertoire of vectors with altered antigenic properties, packaging capabilities, and/or cellular tropisms as compared with current AAV vectors.Type: GrantFiled: November 10, 1999Date of Patent: December 10, 2002Assignee: The University of North Carolina at Chapel HillInventors: Joseph E. Rabinowitz, Richard Jude Samulski, Weidong Xiao